AngioDynamics announced the launch of the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a new clinical study aimed at evaluating the efficacy and safety of their AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).
Learn More
AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
The AlphaVac system is an off the shelf, easy to assemble, emergent mechanical aspiration device, allowing for efficient procedure time…
Today, localized therapy options are limited in providing physicians and patients with a customizable and confident treatment. Most options come…
“The acquisition of Auryon brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment…
It takes a team of talented people to become one of the world’s leading providers of innovative medical devices.
The deep commitment and contributions of our employees helped to build a global company that’s pioneering new ways to improve patient outcomes.
If you find the idea of joining a dynamic team that’s dedicated to improving the lives of patients appealing, we invite you to review our available opportunities.
AngioDynamics is proud to celebrate our 18th year of being listed on the @Nasdaq Exchange with this display in NYC's Times Square.
Congratulations to our partners @AnasSafadi8, Dr. Danavi, and Dr. Yehyawi on a monumental case using the AlphaVac F18 System! We are proud to be your partners in patient care. Learn more about the AlphaVac System at https://alpha-vac.com
https://bit.ly/Angio-risk-info
We are proud to announce that @MSKCancerCenter, led by Principal Investigator Dr. Jonathan Coleman, is officially active and enrolling patients for the PRESERVE Study. This marks a major milestone in our efforts to expand treatment options for patients with prostate cancer!
We are looking for a motivated, experienced Assoc. Product Manager to join our Restorative Flow Therapies team. Mktg Dir. @PeteMakula explains why this work is vitally important & what he’s looking for in a candidate. Visit https://us61e2.dayforcehcm.com/CandidatePortal/en-US/angio/Site/AngioCareers/Posting/View/1321 to learn more.
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
Latham, NY (HQ)
Glens Falls, NY (Manufacturing)
Queensbury, NY (Manufacturing)
Marlborough, MA (R&D)
Amsterdam, NL (International HQ)
São Paulo, BR (Brazil Office)
Oakville, CA (Canada Office)
Hong Kong, HK (Asia Pacific Regional Office)
Rehovot, IL (Israel Office)
